As of January 22, 2025, Taysha Gene Therapies (TSHA) has a market cap of $0.31 billion USD. According to our data, Taysha Gene Therapies is ranked No.6636 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 22, 2025 | $0.31 B |
-11.56%
|
Dec 31, 2024 | $0.35 B |
-2.26%
|
Dec 29, 2023 | $0.36 B |
-21.68%
|
Dec 30, 2022 | $0.46 B |
-80.60%
|
Dec 31, 2021 | $2.39 B |
-56.10%
|
Dec 31, 2020 | $5.44 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
Sarepta Therapeutics
SRPT
|
$11.09 B |
0.000 M
|
USA
|
REGENXBIO
RGNX
|
$0.39 B |
-0.000 M
|
USA
|
Voyager Therapeutics
VYGR
|
$0.30 B |
-0.000 M
|
USA
|
uniQure
QURE
|
$0.82 B |
0.000 M
|
Netherlands
|
Adverum Biotechnologies
ADVM
|
$92.99 M |
-0.000 M
|
USA
|
Editas Medicine
EDIT
|
$0.11 B |
-0.000 M
|
USA
|
Intellia Therapeutics
NTLA
|
$1.12 B |
0.000 M
|
USA
|
bluebird bio
BLUE
|
$76.22 M |
0.000 M
|
USA
|
Solid Biosciences
SLDB
|
$0.12 B |
-0.000 M
|
USA
|
MeiraGTx
MGTX
|
$0.47 B |
-0.000 M
|
USA
|
Passage Bio
PASG
|
$36.81 M |
0.000 M
|
USA
|
Generation Bio
GBIO
|
$63.83 M |
-0.000 M
|
USA
|
Market Cap | = | TSHA Stock Price | * | TSHA Shares Outstanding |
= | $1.53 | * | 0.20 B | |
= | $0.31 B |